School of Environmental and Chemical Engineering, Shanghai University, China.
School of Life Sciences, Shanghai University, China.
Curr Med Chem. 2024;31(20):2921-2943. doi: 10.2174/0929867330666230416153301.
Diabetes mellitus has become a serious life-threatening disease. As one of the new drugs for the treatment of diabetes, GLP-1 receptor agonists have attracted a lot of attention. Compared with traditional hypoglycemic drugs, GLP-1 receptor agonists have good safety and tolerability. To a certain extent, they overcome the problem of the short half-life of natural GLP-1 and can exist stably in patients for a long time, achieving good results in the treatment of diabetes, as well as improving the symptoms of some complications. The GLP-1 receptor agonists in the market are all peptide drugs. Compared with peptide drugs, small molecule agonists have the advantages of low cost and oral administration. In this article, we review the recent research progress of GLP-1 receptor agonists.
糖尿病已成为一种严重威胁生命的疾病。GLP-1 受体激动剂作为治疗糖尿病的新药之一，受到了广泛关注。与传统的降糖药物相比，GLP-1 受体激动剂具有良好的安全性和耐受性。在一定程度上克服了天然 GLP-1 半衰期短的问题，可以在患者体内稳定存在很长时间，在治疗糖尿病方面取得了良好的效果，同时改善了一些并发症的症状。目前市场上的 GLP-1 受体激动剂均为肽类药物。与肽类药物相比，小分子激动剂具有成本低、可口服的优点。本文就 GLP-1 受体激动剂的研究进展作一综述。
